$0.01
(Market cap
$2,737 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
15.6
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-4.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.9
-
Face value
--
-
Shares outstanding
370,864,669
5 Years Aggregate
CFO
$-280.44 Mln
EBITDA
$-470.96 Mln
Net Profit
$-433.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| 79.8 | 2.6 | 70.3 | 60.9 | 68.4 | -15.0 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| 207.5 | -47.0 | -65.1 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
|
7.4 | 2,737.0 | 4.5 | -668.2 | -15,198.8 | -335.5 | -- | 15.6 |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 90.0 | 6,826.3 | 51.2 | -334.9 | -636.8 | -53.3 | -- | 8.8 | |
| 43.3 | 9,271.6 | 2,100.4 | 409.3 | 23.8 | 11.5 | 22.7 | 2.7 | |
| 49.3 | 3,355.3 | 18.7 | -252.2 | -1,047.2 | -96.5 | -- | 10.4 |
Shareholding Pattern
View DetailsAbout ATAI Life Sciences BV (ATAI)
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation... of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. Read more
-
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
-
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ATAI Life Sciences BV (ATAI)
What is the current share price of ATAI Life Sciences BV (ATAI) Today?
The share price of ATAI Life Sciences BV (ATAI) is $7.36 (NASDAQ) as of 28-Aug-2026 13:33 EDT. ATAI Life Sciences BV (ATAI) has given a return of 68.4% in the last 3 years.
What is the current PB & PE ratio of ATAI Life Sciences BV (ATAI)?
Since, TTM earnings of ATAI Life Sciences BV (ATAI) is negative, P/E ratio is not available.
The P/B ratio of ATAI Life Sciences BV (ATAI) is 15.57 times as on 21-Aug-2026, a 347 premium to its peers’ median range of 3.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.38 |
4.09 |
2024 |
-1.43 |
1.83 |
2023 |
-5.57 |
0.92 |
2022 |
-2.77 |
1.62 |
2021 |
-6.87 |
3.06 |
What is the 52 Week High and Low of ATAI Life Sciences BV (ATAI)?
The 52-week high and low of ATAI Life Sciences BV (ATAI) are Rs 7.45 and Rs 3.27 as of 29-Aug-2026.
What is the market cap of ATAI Life Sciences BV (ATAI)?
ATAI Life Sciences BV (ATAI) has a market capitalisation of $ 2,737 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ATAI Life Sciences BV (ATAI)?
Before investing in ATAI Life Sciences BV (ATAI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.